Learn More
The Rome diagnostic criteria for the functional bowel disorders and functional abdominal pain are used widely in research and practice. A committee consensus approach, including criticism from multinational expert reviewers, was used to revise the diagnostic criteria and update diagnosis and treatment recommendations, based on research results. The(More)
How irritable bowel syndrome (IBS) and itstreatment affect quality of life (QOL) is important. Todevelop a quality-of-life measure specific to irritablebowel syndrome, items were generated using a conceptual model and qualitative interviews with personsdiagnosed using the Rome criteria. Symptom frequency andbothersomeness indices were created.(More)
To understand the disorders of bowel motility, it is important to know the range of bowel patterns in the general population. We have devised a brief self-administered questionnaire which, when used among a group of 789 students and hospital employees, disclosed that 94.2% had stool frequencies between three per day and three per week, and that 17.1% had(More)
T he irritable bowel syndrome (IBS) is part of the larger group of functional gastrointestinal (GI) disorders that, despite differences in location and symptom patterns, share common features with regard to their motor and sensory physiology, central nervous system (CNS) relationships, and the approach to patient care. 1 IBS is a functional bowel disorder(More)
BACKGROUND Effective treatments for irritable bowel syndrome with constipation (IBS-C) are lacking. AIM To assess the efficacy and safety of lubiprostone in IBS-C. METHODS A combined analysis was performed among 1171 patients with a Rome II diagnosis of IBS-C in two phase-3 randomized trials of lubiprostone 8 mcg vs. placebo twice daily for 12 weeks.(More)
BACKGROUND & AIMS Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe(More)
BACKGROUND Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation. AIM To assess the efficacy and safety of three lubiprostone doses for irritable bowel syndrome with constipation. METHODS 195 irritable bowel syndrome with constipation patients received daily(More)